We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Roche Sells Drugs of Abuse Testing Business to Varian

By HospiMedica staff writers
Posted on 12 Feb 2003
In a move to divest a business whose market is not important to the company's current strategy, Roche Diagnostics (Basel, Switzerland) has sold its worldwide nonclinical drugs of abuse testing (DAT) business to Varian, Inc. More...
(Palo Alto, CA) for an undisclosed amount.

Included in the sale were Roche's OnTrak TesTcup, OnTrak TesTstik, OnSite alcohol and Intect line of testing devices, all commonly used for illicit drug screening in the workplace and in the criminal justice system. The sale does not include Roche's drugs of abuse testing products used by clinical and hospital laboratory customers. Roche will continue to sell and support the OnTrak TesTcard 9 drugs of abuse testing product and all Abuscreen Online assays for drug abuse.

"When reviewing other companies who were interested in purchasing this business, we sought buyers who were closely aligned with the marketplace to continue growing this business,” said Martin Madaus, president and CEO of Roche Diagnostics, North America.





Related Links:
Roche Diagnostics
Varian

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
HPV Test
Allplex HPV28 Detection
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.